276 related articles for article (PubMed ID: 16917213)
41. [Anticancer drugs used in medicine and being in clinical research].
Malinowska K; Modranka R; Kedziora J
Pol Merkur Lekarski; 2007 Sep; 23(135):165-9. PubMed ID: 18080687
[TBL] [Abstract][Full Text] [Related]
42. Inhibition of pre-mRNA splicing by cisplatin and platinum analogs.
Schmittgen TD; Ju JF; Danenberg KD; Danenberg PV
Int J Oncol; 2003 Sep; 23(3):785-9. PubMed ID: 12888918
[TBL] [Abstract][Full Text] [Related]
43. Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate.
Brouwers EE; Tibben MM; Rosing H; Hillebrand MJ; Joerger M; Schellens JH; Beijnen JH
J Mass Spectrom; 2006 Sep; 41(9):1186-94. PubMed ID: 16929560
[TBL] [Abstract][Full Text] [Related]
44. [Experimental study on carboplatin toxicity--a comparison with cisplatin].
Suzuki K; Usami T; Sudoko H; Ohtawara Y; Tajima A; Kawabe K; Aso Y
Gan To Kagaku Ryoho; 1988 Jul; 15(7):2153-8. PubMed ID: 3293538
[TBL] [Abstract][Full Text] [Related]
45. Kinetic study on the reactions of platinum drugs with glutathione.
Hagrman D; Goodisman J; Souid AK
J Pharmacol Exp Ther; 2004 Feb; 308(2):658-66. PubMed ID: 14610218
[TBL] [Abstract][Full Text] [Related]
46. Synthesis and activity of a trinuclear platinum complex: [{trans-PtCl(NH3)2}2mu-{trans-Pt(3-hydroxypyridine)2(H2N(CH2)6NH2)2}]Cl4 in ovarian cancer cell lines.
Tayyem H; Huq F; Yu JQ; Beale P; Fisher K
ChemMedChem; 2008 Jan; 3(1):145-51. PubMed ID: 17963210
[TBL] [Abstract][Full Text] [Related]
47. Comparative protein binding, stability and degradation of satraplatin, JM118 and cisplatin in human plasma in vitro.
Bell DN; Liu JJ; Tingle MD; Rattel B; Meyer TU; McKeage MJ
Clin Exp Pharmacol Physiol; 2008 Dec; 35(12):1440-6. PubMed ID: 18671714
[TBL] [Abstract][Full Text] [Related]
48. In vitro evaluation of dichloro-bis(pyrazole)palladium(II) and dichloro-bis(pyrazole)platinum(II) complexes as anticancer agents.
Keter FK; Kanyanda S; Lyantagaye SS; Darkwa J; Rees DJ; Meyer M
Cancer Chemother Pharmacol; 2008 Dec; 63(1):127-38. PubMed ID: 18350297
[TBL] [Abstract][Full Text] [Related]
49. The novel platinum(IV) complex LA-12 induces p53 and p53/47 responses that differ from the related drug, cisplatin.
Hrstka R; Powell DJ; Kvardova V; Roubalova E; Bourougaa K; Candeias MM; Sova P; Zak F; Fåhraeus R; Vojtĕsek B
Anticancer Drugs; 2008 Apr; 19(4):369-79. PubMed ID: 18454047
[TBL] [Abstract][Full Text] [Related]
50. Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer.
Tozawa K; Oshima T; Kobayashi T; Yamamoto N; Hayashi C; Matsumoto T; Miwa H
Anticancer Res; 2008; 28(4B):2087-92. PubMed ID: 18751380
[TBL] [Abstract][Full Text] [Related]
51. Cellular accumulation and cytotoxicity of macromolecular platinum complexes in cisplatin-resistant tumor cells.
Garmann D; Warnecke A; Kalayda GV; Kratz F; Jaehde U
J Control Release; 2008 Oct; 131(2):100-6. PubMed ID: 18691617
[TBL] [Abstract][Full Text] [Related]
52. Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin.
Holzer AK; Manorek GH; Howell SB
Mol Pharmacol; 2006 Oct; 70(4):1390-4. PubMed ID: 16847145
[TBL] [Abstract][Full Text] [Related]
53. The influence of tumour microenvironmental factors on the efficacy of cisplatin and novel platinum(IV) complexes.
Mellor HR; Snelling S; Hall MD; Modok S; Jaffar M; Hambley TW; Callaghan R
Biochem Pharmacol; 2005 Oct; 70(8):1137-46. PubMed ID: 16139250
[TBL] [Abstract][Full Text] [Related]
54. In vitro antitumor activity of 2-acetyl pyridine 4n-ethyl thiosemicarbazone and its platinum(II) and palladium(II) complexes.
Kovala-Demertzi D; Boccarelli A; Demertzis MA; Coluccia M
Chemotherapy; 2007; 53(2):148-52. PubMed ID: 17308381
[TBL] [Abstract][Full Text] [Related]
55. Organic cation transporter OCT/SLC22A and H(+)/organic cation antiporter MATE/SLC47A are key molecules for nephrotoxicity of platinum agents.
Yonezawa A; Inui K
Biochem Pharmacol; 2011 Mar; 81(5):563-8. PubMed ID: 21144842
[TBL] [Abstract][Full Text] [Related]
56. [Cross resistance of a new platinum analogue, ACT-078, to CDDP and CBDCA].
Misawa T; Higashide K; Konda C; Maeda O; Hasegawa N; Kikkawa F; Tomoda Y
Gan To Kagaku Ryoho; 1995 Mar; 22(4):569-71. PubMed ID: 7887652
[No Abstract] [Full Text] [Related]
57. Relationship between DNA-reactivity and cytostatic effect of two novel bile acid-platinum derivatives, Bamet-UD2 and Bamet-D3.
Martinez-Diez MC; Larena MG; Serrano MA; Macias RI; Izco-Basurko I; Marin JJ
Anticancer Res; 2000; 20(5A):3315-21. PubMed ID: 11062759
[TBL] [Abstract][Full Text] [Related]
58. In vitro and in vivo antitumour effects of novel, orally active bile acid-conjugated platinum complexes on rat hepatoma.
Barbara C; Orlandi P; Bocci G; Fioravanti A; Di Paolo A; Natale G; Del Tacca M; Danesi R
Eur J Pharmacol; 2006 Nov; 549(1-3):27-34. PubMed ID: 16978599
[TBL] [Abstract][Full Text] [Related]
59. Modification of the physicochemical and pharmacological properties of anticancer platinum compounds by commercial 5-fluorouracil formulations: a comparative study using cisplatin and carboplatin.
Fournier C; Hecquet B; Bastian G; Khayat D
Cancer Chemother Pharmacol; 1992; 29(6):461-6. PubMed ID: 1568289
[TBL] [Abstract][Full Text] [Related]
60. Stress response inhibits the nephrotoxicity of cisplatin.
Hanigan MH; Deng M; Zhang L; Taylor PT; Lapus MG
Am J Physiol Renal Physiol; 2005 Jan; 288(1):F125-32. PubMed ID: 15353400
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
